This medicine is authorised for use in the European Union.


Poteligeo is a cancer medicine used to treat mycosis fungoides and Sezary syndrome – two cancers of blood cells that affect mainly the skin. It is used in patients who have received previous treatment by mouth or injection.

Both mycosis fungoides and Sezary syndrome belong to a group of rare cancers (cutaneous T-cell lymphomas), and Poteligeo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 14 October 2016. Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation

Poteligeo contains the active substance mogamulizumab.

This EPAR was last updated on 06/09/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Sezary Syndrome
  • Mycosis Fungoides
Anatomical therapeutic chemical (ATC) code

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Kyowa Kirin Holdings B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Bloemlaan 2
2132NP Hoofddorp
The Netherlands

Product information

01/09/2023 Poteligeo - EMEA/H/C/004232 - R/0021

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating
2 ratings
1 rating